The combination of EGFR-CAR-T cell therapy and radiotherapy showed an enhanced anti-tumor effect in both the in situ TNBC mouse model with normal immune function and that with immunodeficiency. This combination therapy not only enhanced the infiltration of CAR-T cells in the tumor, but also did not increase the risk of CRS. The gene discussed is EGFR; the disease is neoplasm.